KBC Group
VERA icon

KBC Group’s Vera Therapeutics VERA Stock Holding History

KBC Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$41K Hold
1,282
– – ﹤0.01% 1760
2026
Q2 		$55K Hold
1,282
– – ﹤0.01% 1679
2026
Q1 		$52K Sell
1,282
-670
-34% -$28.9K ﹤0.01% 1637
2025
Q4 		$99K Hold
1,952
– – ﹤0.01% 1290
2025
Q3 		$57K Buy
1,952
+1,250
+178% +$28.9K ﹤0.01% 1605
2025
Q2 		$17K Sell
702
-1,775
-72% -$39.9K ﹤0.01% 1709
2025
Q1 		$59K Hold
2,477
– – ﹤0.01% 1740
2024
Q4 		$105K Buy
2,477
+1,387
+127% +$61.4K ﹤0.01% 1525
2024
Q3 		$48K Hold
1,090
– – ﹤0.01% 1731
2024
Q2 		$39K Hold
1,090
– – ﹤0.01% 1742
2024
Q1 		$47K Buy
+1,090
New +$38.8K ﹤0.01% 1600

Other funds holding VERA

Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

KBC Group's VERA Position: Q3 2026 in Review

KBC Group held its Vera Therapeutics (VERA) position steady in Q3 2026 at 1,282 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #1760.

KBC Group first reported a position in VERA in Q1 2024 and has held it in 11 quarters since. The position peaked at $105K in Q4 2024. 71 funds tracked by Wall St. Rank hold VERA as of Q3 2026.

  • KBC Group held 1,282 shares of Vera Therapeutics worth $41K as of Q3 2026.
  • KBC Group left its Vera Therapeutics share count unchanged in Q3 2026.
  • Vera Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1760 holding.
  • KBC Group first reported a position in Vera Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • KBC Group's Vera Therapeutics position peaked at $105K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.